RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

Starting soon · Phase 4

Conditions studied: Overweight and Obese Adults

In brief

To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.

Key facts

Study ID

NCT07301437

Run by

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

People needed

120

Starts

2026-05-01

Expected to finish

2027-08-31

Last updated by the study team

2026-03-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)
• Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.
• No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.

You may not qualify if…

• Allergy to liraglutide, orlistat or excipients
• Severe liver and kidney dysfunction: ALT or AST> three times the upper limit of normal, or eGFR <30 mL/min
• Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism
• Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers
• Pregnant or lactating women
• Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.